Caption Management LLC Invests $484,000 in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Caption Management LLC bought a new stake in Merit Medical Systems, Inc. (NASDAQ:MMSI - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 5,000 shares of the medical instruments supplier's stock, valued at approximately $484,000.

Several other institutional investors have also recently added to or reduced their stakes in MMSI. Norges Bank purchased a new position in shares of Merit Medical Systems during the 4th quarter worth about $66,638,000. Raymond James Financial Inc. purchased a new stake in Merit Medical Systems in the fourth quarter valued at approximately $48,926,000. FMR LLC raised its stake in Merit Medical Systems by 31.6% during the fourth quarter. FMR LLC now owns 2,076,439 shares of the medical instruments supplier's stock worth $200,833,000 after purchasing an additional 499,193 shares during the period. Groupama Asset Managment purchased a new position in Merit Medical Systems during the fourth quarter worth approximately $38,688,000. Finally, Bryn Mawr Capital Management LLC acquired a new position in shares of Merit Medical Systems in the 4th quarter valued at $36,057,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Merit Medical Systems

In related news, CFO Raul Jr. Parra sold 12,451 shares of the company's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $98.81, for a total value of $1,230,283.31. Following the sale, the chief financial officer now directly owns 24,201 shares of the company's stock, valued at $2,391,300.81. This represents a 33.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Stephen C. Evans sold 5,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $105.31, for a total transaction of $526,550.00. Following the transaction, the director now directly owns 4,657 shares of the company's stock, valued at approximately $490,428.67. This represents a 51.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 109,132 shares of company stock valued at $11,139,521 in the last three months. Corporate insiders own 3.70% of the company's stock.

Merit Medical Systems Stock Down 0.3 %

Shares of NASDAQ MMSI traded down $0.26 during trading on Friday, reaching $95.83. 694,483 shares of the stock were exchanged, compared to its average volume of 511,134. The company has a market capitalization of $5.66 billion, a price-to-earnings ratio of 46.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.70. The business's 50-day moving average price is $97.00 and its 200 day moving average price is $100.47. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. Merit Medical Systems, Inc. has a twelve month low of $80.02 and a twelve month high of $111.45.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its earnings results on Thursday, April 24th. The medical instruments supplier reported $0.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.75 by $0.11. The business had revenue of $355.35 million for the quarter, compared to analyst estimates of $352.57 million. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The company's revenue for the quarter was up 9.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.77 earnings per share. As a group, equities analysts forecast that Merit Medical Systems, Inc. will post 3.37 EPS for the current fiscal year.

Analysts Set New Price Targets

MMSI has been the topic of several research reports. Barrington Research cut their target price on Merit Medical Systems from $111.00 to $103.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Raymond James dropped their price target on Merit Medical Systems from $116.00 to $108.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Wells Fargo & Company set a $106.00 price objective on Merit Medical Systems and gave the company an "overweight" rating in a research note on Friday, April 25th. Canaccord Genuity Group dropped their target price on shares of Merit Medical Systems from $127.00 to $108.00 and set a "buy" rating for the company in a research report on Friday, April 25th. Finally, Robert W. Baird reduced their price target on shares of Merit Medical Systems from $111.00 to $110.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Merit Medical Systems has an average rating of "Moderate Buy" and a consensus target price of $107.78.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.